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ABSTRACT
Differentiation and proliferation are known to be influenced by steroid stimulation. The
steroid receptor activator (SRA) RNA is a large RNA transcript indicated to be an epigenetic
regulatory component in the steroid receptor coactivator-1 (SRC-1) acetyltransferase complex. It
is needed for a response to steroid hormones by tumor cells. However, this activity is hindered by
suppressive RNA binding proteins like the SMRT/HDAC1-associated repressor protein (SHARP),
which binds the STR7 domain of SRA RNA through its four RNA recognition motifs (RRMs); it
is not fully understood how SHARP executes this role as there are no SRA RNA-SHARP
structures available for study. Traditional methods have determined the secondary structure of
STR7[2] and the Leeper group used NMR to determine the structures of SHARP RRMs, but these
techniques have shown to be limited in the case of SRA RNA-SHARP complexes because of its
size and flexibility.
In this study, SHARP2 was purified and complexed with STR7 RNA synthesized from
oligonucleotides and T7 RNA polymerase. Small angle X-ray scattering was then used to
investigate and compare the structures of the three-dimensional conformations of SRA RNASHARP2 complexes to the free-SHARP2 and the free-STR7 RNA structures to better understand
how SHARP carries out its function and thereby improve therapeutic treatments for cancer. The
data obtained showed structural changes in the RNA and an increase in the radius of gyration,
which supports the hypothesis that SHARP RRM 2 contributes to a reduction in the SRA RNA
coactivator activity by remodeling the RNA structure while the remaining SHARP RRMs may act
simply as recruitment modules. Therefore, if we can determine how SHARP suppresses SRA RNA
activity, then small molecules can be designed to counter SRA RNA activity and improve cancer
therapeutics.
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CHAPTER 1. INTRODUCTION
1.1 Steroid receptor activator RNA (SRA RNA) and the SMRT/HDAC1-associated repressor
protein (SHARP)
Steroid receptor activator RNA (SRA RNA) is an epigenetic regulator (0.87 kB) long noncoding RNA (lncRNA),

[1, 2]

which is associated to the ribonucleoprotein (RNP) complex of the

steroid receptor coactivator 1 (SRC-1).

[1]

lncRNAs are transcribed RNAs that are two hundred

nucleotides or greater and are free of obvious open reading frames, hence non-coding for protein
synthesis. [3] SRA RNA has the benefit among the lncRNAs (200 nt-100kb) to be sufficiently short
(less than one kilobase) for the use of mechanism studies, but also long enough to encompass
numerous characteristics of lncRNAs. [2] SRA (Figure 1.1) is made up of four domains of which,
domains I-III are the most conserved among species

[2]

and are the essential part of the RNA.

Domain II is located in the ligand binding domain of androgen receptors (ARs) and it comprises
the subdomain STR-7 that is also known as structure-7; [2] domain II contains helices 10-14 (H10H14) whereas STR7 encloses H12 and H13. The STR7 domain has four loops and it is shaped like
a bended arm.

[2]

SRA has shown to be a coactivator to multiple steroid stimulated receptors

[2]

such as the estrogen receptors alpha (ERα) and to form complexes with nuclear receptor (NR)
corepressor proteins such as SHARP. [2] ERα is located within the ligand independent domain of
the activation function (AF-1) in the N-terminal domain (NTD) of ARs. [1] SRA participates in a
variety of developmental processes

[2]

and it has been linked to multiple diseases.

Overexpression of SRA leads to the proliferation of cancer cells.
Organization published an article

[4]

[1]

[2]

In 2018, the World Health

stating that cancer was the first or second leading cause of

death before age 70 in 91 of 172 countries in 2015.

[4]

However, in 2018, it was cited to be the

leading cause of death [4] in both males and females, breast cancer being the leading cause among
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women and prostate cancer being the second cause among men. [4] The increase was due to the
drops in the death rates of coronary heart disease and stroke, compared to cancer in many countries,
with fast population growth and aging populations worldwide.

[4]

ERs are related to breast cancer

while ARs are related to prostate cancer. ARs and ERs are receptor antagonists that have been the
target

[1]

for the treatments of these types of cancer.

[1]

The drugs for the target receptors show

limitations, [1] therefore, finding more effective cancer therapy is of importance. However, a better
understanding of the biological pathways, structures, and how proteins interact with different
macromolecules is required. Biomolecules such as steroid receptor activator RNA (SRA RNA) are
of interest for they are involved in cancer cells proliferation. This activity is regulated by other
factors and suppressor proteins like SRA stem-loop interacting RNA binding protein (SLIRP) and
SHARP reduce its activity. [5]

2

Figure 1.1: Structure of SRA RNA, showing its 4 domains. The STR7 domain is a subdomain of
domain II and it encompasses helices 12 and 13. Adapted from Novikova et al. [2]

In 2000, Ordentlich et al discovered SHARP while working with the conserved carboxyl
terminus of the NR corepressor [5] silencing mediator of retinoid acid and thyroid hormone receptor
(SMRT) as a bait to pull out NR-interacting partners via a yeast two-hybrid experiment. [5] SHARP
(Figure 1.2) is a transcriptional repressor [2] that is found in multiple organs and tumor cells such
as the testis and the breast cells.

[5]

SHARP has four RNA recognition motifs (RRMs) and binds

the STR7 domain of SRA through three of its conserved RRMs N-termini.
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[5,6]

SHARP engages

histones deacetylase complexes (HDAC) that [5] are essential for repression regulation of different
genes involved in cell death, signal transduction, and cell growth. [7] This engagement brings SRA
RNA and HDAC together leading to the modification of the chromatin state and the repression of
transcription. [7,8] It has been proposed that SRA RNA activity can be reduced and/or silenced by
this interaction.

[5-8]

Dr. Leeper’s group has used NMR to determine the structure of RRMs

domains of human SHARP including RRM 2 (Figure 1.3), [9] while other domains from SHARP
have had their structures determined via crystallography (4P6Q: Arieti et al 2014; 2RT5: Mikami
et al 2014; 1OW1: Schwabe and Ariyoshi 2003).

A

1

234

N

C

B

Figure 1.2: A) Schematic representation of SHARP protein. B) Crystal structures of
the different domains of SHARP. Adaptation from Leeper’s group, Arieti et al 2014
(4P6Q, RRMs domain in blue), Mikami et al 2014 (2RT5, HDAC associated domain
in green), Schwabe and Ariyoshi 2003 (1OW1, SPOC domain in red).
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Figure 1.3: PDB structure of SHARP RRM domain 2. Leeper and Caporoso
1.2 Nuclear Magnetic Resonance
Nuclear Magnetic Resonance (NMR) is a high resolution spectroscopic technique used to
study the structure [10] of molecular interactions, the dynamics of molecules and the composition
of biological solutions mixtures.

[10,11]

It was first introduced by Isidor Rabi in 1938 and later

became a well-used technique for the study of biomolecules structures as extensive work and
improvement have been done by Edward Mills Purcell and Felix Bloch who consequently won the
Nobel Prize in Physics in 1952. [12] NMR utilizes the effect of robust magnetic field, [12,13] causing
the sample to be polarized [12] as the nuclei spin and adopt magnetic moments [12] that are parallel
to the applied field, [12] allowing the sample to be analyzed.

[12]

Structural information from the

analysis can be acquired, [14] however, only sparse data are obtained as the molecular weight of the
complex increases.

[13,14]

1.3 Small Angle X-Ray Scattering (SAXS)
STR7-SHARP2 complex is large and flexible and it cannot be accommodated by NMR and

NMR alone cannot be used to describe the disordered loops or domains’ conformations. In
5

addition, X-ray crystallography cannot be used to record these conformations as it is difficult to
crystallize flexible macromolecules. [15] The proteins involved in the regulation of gene expression
are inherent unfolded proteins, making crystallization difficult.

[11,15]

Given these challenges, the

use of the small-angle X-ray scattering (SAXS) is a good alternative and a complimentary
technique to NMR and crystallography.
Small angle X-ray scattering is a solution scattering technique in which a biomolecule
sample/complex is subjected to an incident beam of X-ray. [14] SAXS allows the analysis and
characterization of potential conformational dynamics in solution. [14,16] The data that are obtained
can produce information on the envelopes

[17]

of protein and protein-RNA complexes in solution

and clarify any ambiguity in structural composition (presence of monomer, dimer, etc.). [14,17] This
additional information is unable to be extracted using the NMR technique for large, elongated, or
flexible molecules. Therefore, it can be used to rectify challenges posed by crystallography and
NMR. [18] The SAXS technique is of advantage as it is able to differentiate the folded or unfolded
state of a molecule [18] and give precise details on the size and shape of the molecule. [13,19] This is
useful as interactions between proteins and their substrates or regulators [13] such as SHARP2STR7 can alter the shape of the biomolecule. X-ray scattering offers a valuable means of measuring
such effects. [13] Uchida et al. and Rambo et al. reported that with SAXS, simulation of the natural
environment of a protein if feasible for various solution conditions can be employed.
solution, there is more flexibility in the movement and interactions
exist in three-dimensional space.

[18]

[18]

[14,17]

In

of biomolecules, as they

However, SAXS experiment is very challenging as the

sample’s buffer and the buffer solution [17-20] in the blank must be closely matched to avoid buffer
mismatch, which can severely impair background subtraction and data analysis.
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[18,20]

It is also

very sensitive to sample aggregation and polydispersity, [18] and so, the sample preparation must
be done with care. [18,20]
SAXS utilizes collimated beam of incident X-ray of a distinct sub-nanometer wavelength,
usually 0.05-0.5 nm. [13] When the experiment is conducted at small angles (distance between the
sample and the detector is long), typically 0.1-5º, there is no net energy transfer between the
incident and the scattered waves as SAXS is an elastic scattering method, and the displacement (q)
of the angle of the vectors associated with the scattering X-ray is caused by the incident beam and
not by the transfer of energy from the incident beam. [20] The X-ray beam traverses the sample and
creates scattered X-rays [18] that are collected as two-dimensional (2-D) images on a detector.

[18]

Because each molecule that is present in the sample scatters to a different orientation and when
they scatter evenly [20], the overall displacement q becomes the sum of all the displacements. [18,20]
Although the SAXS profile is recorded as 2-D data, the scattering is averaged over all orientations
to get a one-dimensional (1-D) scattering intensity as a function of q, [18]

= k - k0

θ

Figure 1.4: Basic schematic setup of small angle X-ray scattering experiment

7

where the scattered intensity is magnitude of q dependent and independent from the direction of
scattering vectors. [18] With a background correction, the intensity obtained is then proportional to
q, [18] which is the amplitude of the sum of the incident wave-vector and the scattered wave-vector,
[14]

k = |k| = k 0

[20, 21]

(Eq. 1)

|k 0 | = k = 2π/λ
q = k – k0
|𝑞 | = 𝑞 = 2𝑘 sin 2𝜃 =

4𝜋
𝜆

sin 𝜗

[22]

(Eq. 2)

𝜗 = 2𝜃
k is the wave-vector upon scattering
k0 is the incident wave-vector
λ is the wavelength of the incident beam where 𝜗 is the angle between the incident and the scattered
beams and (Figure 1.4). [18, 20]
SAXS is performed on solution molecules, the n scatterers [20] making up the molecules in
the sample can assume different orientations,

[20]

and since the scattering is from an ensemble of

atoms, a more useful approach to SAXS is the use of continuous distribution of the scattering
length density ρ(r) [20] that is a sum of the scattering displacement from the atoms in a unit volume.
[20]

Scattering of X-rays by a solution of biomolecules depends on the solute concentration in the

sample, [13] the square of each particle size, and the square of the excess scattering length density
or contrast, Δρr(r),

[13,20]

a change between the buffer and an individual particle

sample relative to that of the corresponding solvent volume.

[20]

[20]

present in the

A subtraction of the solvent

scattering from that of the sample is performed to account for the molecule scattering. [13,20]
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The integration of the 2D data into 1D data through Fourier transform yields the Guinier
plot (Figure 1.5A) [20,21] that is the plot of the intensity I at q, I (q) vs. q at low angle. [21] Solution
scattering requires both mono-dispersity [17-21] and the absence of inter-molecular interactions. [21]
Low angle SAXS data shows if there are inter-particle interactions, aggregations or repulsive
interactions in the sample, [21] buffer mismatch, and possible sensitivity to pH; and deviation from
the Guinier curve (straight line) is an indication of intermolecular interaction or aggregation.

[21]

The “Guinier region” allows the evaluation of the radius of gyration as well as the intensity at zero
angle, I (0), [16] and it is also a characteristic for the overall dimension of the particle.

[20,21]

Subsequent calculations give important quantitative parameters including the radius of
gyration (Rg), the maximum particle diameter (Dmax), the molecular mass (MM), and the hydrated
particle volume (Vp), [13] which provide direct information about the general shape of the molecules
in solution, the size, and the oligomeric state. [13] The radius of gyration is the average of the square
center-of-mass [13, 23] distances in the molecule subjected by the scattering length density. [13, 23] It
[24]

describes the distribution of the mass of a macromolecule

relative to its center of gravity

[24]

and measures in this manner the overall size of the molecule; [13,23] it is a reliable approximation,
particularly for unstructured

[13,25]

complexes and it indicates the particle density.

[13,25]

Even

though the Rg is obtained from the Guinier, it is also gained from the particle distance distribution
function p(r), which is obtained from the indirect Fourier transformation of the experimental
scattering data.

[25]

The p(r) plot, a description of particle sample in real space, is a histogram of

the distances among all likely pairs of atoms in a particle

[25]

inter-particle interactions, and polydispersity of the sample.
R2g =

D
∫0 max r2p(r)dr
D
2 ∫0 max p(r)dr

, [25]

and it is sensitive to concentration,

[18]

Rg is given by equation 3,
(Eq. 3)

where Dmax is the maximum dimension of the molecule under study. P(r) is given by equation 4,
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p(r ) =

r2
2π2

∞ s2 I(s) sin(sr)

∫0

sr

dr , [25]

(Eq. 4)

where I (s) is the scattering pattern of the particle and r is the scattering distance of the particle.

Figure 1.5 A) Guinier plot showing the “Guinier region” (Adapted from slide 23, Weiss 2016).
[17]
B) Kratky plot showing the folded and unfolded states of a biomolecule at wide angle; the
red, blue, and green semi-parabolic curves show the unfolded state, while the black parabolic
curve shows the folded state. Adapted Tainer et al. [13]

Further analysis gives the Kratky plot (Figure 1.5B), I*q2 vs. q curve, which at wide angles
displays distinctive parabolic behaviors of the molecule.

[17]

Wide angle X-ray scattering signifies

that the distance between the sample and the detector is shorter. The Kratky curve is sensitive to
the morphology and compactness of particles [21] and it thereby helps distinguish the unfolded and
the folded states of the biomolecules. [21]
After the determination of the different parameters and curves, with the availability of
advanced computational techniques, [13] low resolution 3D structures of the biomolecules can be
determined. [13] Important SAXS data are used in the determination of an ab initio reconstruction
algorithm.

[13]

The ab initio methods rebuild atom shapes as closely packed beads
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[13,20]

inside a

volume that is typically controlled by D max.

[13]

Multiple programs such as DAMMIN for the

determination of ab initio shape using a dummy atom model, [16] bodies for that of ab initio shape
with geometrical bodies, [16] and GASBOR for the rebuilding of a protein structure through a chainlike

[16]

collective of dummy residues is utilized.

[16]

In this process, the scattering intensities are

calculated using spherical harmonics [13] after the assignment of a particle or non-particle phase to
the beads.

[13]

The resulting inconsistency is then assessed between the experimental and the

computed scattering intensities.

[13]

Nonetheless, the solution is furthermore submitted to

limitations due to a penalty term that requires that the beads be linked and the model compacted to
guarantee that physically feasible low-resolution structures, which describe the overall shape and
size of the particles are generated. [13]
1.4 Hypothesis and approach
1.4.1 Hypothesis
Many tumor cells need epigenetic processes for response to steroid hormones. Overexpression of SHARP hinders the activity of SRA RNA. [5] Therefore, understanding the structure
- activity relationship between SRA RNA and SHARP can help to better understand how and
where SHARP recognizes the SRA RNA and thereby comprehend fundamental features of
molecular RNA recognition of lncRNAs. In this way, small molecules can be designed to
counteract SRA RNA activity for better therapeutics for cancer. Previous works have shown that
SHARP RRMs 1, 3, and 4 serve as recruitment modules. We hypothesize that the binding of
SHARP RRM 2 to STR7 triggers a conformational change in STR7 and consequently remodels
and contributes to a reduction in the SRA RNA coactivator activity.
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1.4.2 Approach
SHARP 2 protein was expressed using BL21 DE3, Escherichia coli competent cells, which
are good for expressing protein, and purified using the immobilized metal affinity chromatography
(IMAC). The IMAC is a method used to purify fusion proteins with respect to their affinity to
specific metal ions immobilized by chelation to a matrix on a column. It is suited for certain
proteins such as recombinant proteins, where a poly-histidine tag is attached to the protein.
SHARP2 was finally purified using size exclusion chromatography (SEC). STR7 RNA was
synthesized using oligonucleotides and T7 RNA polymerase and then electro-eluted. Electroelution is a technique used to extract nucleic acids from an electrophoresis gel through the
application of a negative current to the nucleic acids, which is subsequently collected on the
positive current side. The nucleic acid sample is further polished using SEC, a method by which
macromolecule complexes in solution are separated by size and/or molecular weight through a
column packed with a Sephadex matrix.

[26]

Because the beads are tightly packed, the larger

molecules are first eluted, followed by the smaller molecules, which travel at a slower rate. Once
the individual molecules were purified, the ribonucleoprotein complex was made and submitted to
SAXS experiment and the data was processed and analyzed.
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CHAPTER 2. MATERIALS AND METHODOLOGY
2.1 Protein expression and Purification
SHARP RRMs 2-4 plasmid was bought from GenScript and designed as N-terminal fusion
of a six-histidine tag followed by a glutathione s-transferase tag (GST, for better expression and
solubility) and a TEV cleavage site containing ampicillin antibiotic resistance. The original EK
cleavage site in pGS-21a vector was removed during the cloning as the KpnI cloning site was
upstream of the EK’s cut site; the EK cleavage site was replaced with TEV. But, RRMs 2-4
construct did not purify with the soluble fraction even though it expressed normally. Therefore, a
site-directed mutagenesis was performed by the Leeper’s group to truncate the target proteins by
adding a stop codon in the predicted sites between domains using Agilent Quikchange II XL Site
Directed Mutagenesis kits following the conditions recommended by the manufacturer. SHARP
RRM 2-4 was separated into RRM 2 and RRM 2-3.
The transformation of plasmid SHARP RRM 2 was performed using 50 µL of BL21-DE3
(Lucigen, Biosearch Technologies), chemically competent Escherichia coli cells, 0.5 µL of
SHARP 2 plasmid, and 950 µL of super optimal broth with catabolite repression (SOC). After an
hour of incubation at 37ºC, the bacteria-plasmid solution was spread on two Luria-Bertani broth
(LB)-agar selection plates, an ampicillin plate and a kanamycin plate for control, for the plasmid
is ampicillin resistant. The plates were then incubated overnight at 37ºC for growth. The colonies
that were formed on the transformation plate were inspected and some were selected and
inoculated into 100 mL of LB media that contained 100 µL of ampicillin, and incubated at 37ºC
overnight for growth. Then twenty-five milliliters of the latter inoculum were pipetted and
transferred into 500 mL of prepared minimal salts (M9) medium (Table 2.1, appendix A) and
incubated at 37ºC. An M9 media allows the control of nitrogen and glucose source for the protein
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and it also allows to label the protein 15N for nuclear magnetic resonance (NMR) purposes. Two
hundred microliters of M9 solution were taken before the addition of the LB-cells inoculum as a
control in the determination of the required cell density OD of 0.4 – 0.6 at 600 nm, for induction.
After an hour of incubation, 200 µL sample of cells-M9 was taken to determine the first cells’
density, using a 96-well plate reader.
From that point, a series of absorbance measurements were taken every 25 to 30 minutes
until the appropriate absorbance for induction was reached, preferably an absorbance of 0.4-0.55.
Once the induction point was reached, the culture was induced with isopropyl-β-D-thiogalactoside
(IPTG) to a final concentration of 1mM IPTG, and the mixture was incubated at 18ºC for 19 hours.
Pre-induction samples were taken and incubated alongside the corresponding large inoculum flask;
the post-induction samples were taken at the end of the incubation. Subsequently, the inoculum
was centrifuged at 8,000 rpm for 15 minutes at 4ºC in SORVALL RC 6 PLUS centrifuge while
the pre and post-induction samples were centrifuged at 13,000 rpm for 3 minutes in the Eppendorf
centrifuge 5418. The supernatant was discarded and the pellets were frozen at -20ºC until needed.
The frozen pellets were later thawed, re-suspended in 60 mL of buffer A to homogenize the
cells (Table 2.2, appendix A), and French pressed. The LenMills G-M French press instrument
utilized a cold metal cell in which the homogenized pellets were loaded in; the metal cell had to
be kept cold to avoid denaturing the protein because the metal cell warmed up as it was being used.
The bacteria were passed three times on the French press under 1500-1700 psi (10342.5-11721.5
kPa). The lysate was centrifuged at 18,000 rpm for 40 minutes at 4ºC; the supernatant was kept
and the pellets were discarded. Subsequently, the supernatant was purified using the immobilized
metal affinity chromatography (IMAC) technique, which utilized His-trap FF, 5ml column (nickel
column), on Bio Rad NGC Chromatography System. SHARP 2 construct has six histidines
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(Figure 2.1A) at its N-terminal end that allow it to bind to the nickel in the column while the nonspecific proteins and impurities are flushed through the column. At low concentration of imidazole,
the six histidine residues in SHARP2 form a complex with the nickel present in the column, and
at higher concentrations of imidazole, the imidazole (Figure 2.1B) competes with the histidines
for the nickel, allowing SHARP2 to be eluted from the column. The supernatant was loaded at 3
mL/min with an isocratic buffer A that had 20 mM of imidazole; the protein was subsequently
eluted in 2 mL fractions through a gradient with buffer B (Table 2.3, appendix A), which
contained 400 mM of imidazole, from 0% to 100% B over 20 mL at 5 mL/min (Figure 2.2).
Samples of the supernatant and the flow through were taken before discarding the flow through,
and the collected fractions pooled into a 3,500 molecular weight cut off (MWCO), 25 mm
SnakeSkin Dialysis Tubing, and dialyzed in a dialysis buffer (Table 2.4, appendix A) overnight
to remove the imidazole.

Figure 2.1: Chemical structure for: A) Histidine and B) Imidazole.
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Figure 2.2: First immobilized metal affinity chromatography of 15N SHARP 2 protein. The first
peak shows the loading of the protein to the column; the drop in the peak to baseline shows the
washing of the protein with buffer A. The second peak illustrates the elution of the protein with a
gradient 0% to 100% buffer B.

Then, a “cleave-and-clear” (cleave the 6 histidine-tag and rerun the cleaved protein) was
performed. The protein was cleaved overnight at room temperature by transferring the dialyzed
protein into a 50 mL tube and adding in ethylene diamine tetra-acetic acid (EDTA) and Tobacco
Etch Virus nuclear-inclusion endopeptidase (TEV protease). TEV protease is a cysteine protease
that recognizes a specific sequence engineered into a construct and is therefore used to cleave
fusion tags from recombinant proteins. EDTA binds to metals present in the sample that would
inactivate the nucleophilic cysteine and allows TEV to cleave the histidine-tag. The cleaved
protein was loaded with buffer A on the IMAC instrument; the flow through was collected and
kept as the protein and a gradient was performed using buffer B from 0% to 100% B to elute any
un-cleaved material from the column (Figure 2.3). Again, samples of the pre and post-TEV, the
second nickel run, and the un-cleaved material were taken. The flow through was dialyzed
overnight in a size exclusion chromatography (SEC) buffer (Table 2.5, appendix A). The pooled
fractions from the gradient were either discarded or re-cleaved after analysis of a protein gel
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electrophoresis to determine the nature of the un-cleaved material. The protein was subsequently
concentrated using Amicon concentrator with 3,500 MWCO 25 mm membrane and checked with
NMR for purity and folding. The concentrated protein was loaded and eluted at 0.6 mL/min on the
SEC column, GE Hiload 16/600 Superdex 75 pg. The column was equilibrated with 2.5 columnvolume (300 ml) of SEC buffer; it has 40 ml void-volume and SHARP 2 protein eluted between
80 - 90 ml (Figure 2.4). The fractions were then pooled, concentrated, and stored at -80ºC until
the intended experiments. The concentrations were calculated using SHARP2 extinction
coefficient, 6990 L/mol*cm.

Figure 2.3: Second immobilized metal affinity chromatography of 15N SHARP 2 protein. The
first peak illustrates the cleave-and-clear flow through, while the second peak shows the elution
of any un-cleaved material and the GST tag following a gradient with buffer B.
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Figure 2.4: Size exclusion chromatography 15N SHARP2 protein, displaying the elution peak.
2.2 RNA synthesis
2.2.1 Purification of T7 RNA polymerase
The purification of T7 RNA polymerase (T7 RNAP) was performed according to the
literature. [27] An overnight culture was made in 2X yeast tryptone broth (2X-YT)-ampicillin with
bacteria from a glycerol stock and incubated at 37ºC overnight. Expression was achieved by adding
10 ml of the latter inoculum to 1L of 2X-YT-ampicillin and incubated at 37ºC. Once the
absorbance reached 0.6 at 600 nm, the culture, total of 2L, was induced with 1 mM IPTG, grew
for 4 hours, centrifuged at 5000 rpm for 30 minutes, and stored in -80ºC freezer.
The frozen pellet was then re-suspended in 60 mL of cold lysis buffer (for 1L: 100 mM TRIS-HCl
pH 8.0 (12.11 g TRIS-HCl), 50 mM KCl (3.728 g KCl), 1 mM EDTA (1 mL of 1M EDTA), 2
mM DTT (1 mL of 1M DTT)) containing 1 tablet of Pierce protease inhibitor and 120µL of DTT.
The cells were then French pressed and the lysate was centrifuged at 10,000 xg (9190 rpm) at 4ºC
for 30 minutes and 65 mL of supernatant was obtained. The supernatant was transferred into a
beaker with a stir bar and stirred in the cold while 35 ml of ammonium sulfate (AS, 325.064 g of
AS into a beaker, added DI H2O to 500 mL mark and heated and stirred until the solution was
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clear, volume to 600 mL, filtered the solution into a bottle using 0.45 µm filter paper, and stored
in the fridge) were added slowly to it over 3 – 5 minutes, to make 35% AS and to help remove
impurities; the dark brown supernatant turned brown yellowish. The mixture was gently stirred
afterwards for an additional 20 minutes in the cold, then centrifuged at 10,000 xg for 30 minutes
at 4ºC. The pellet was discarded and the volume (90 mL) of the supernatant obtained was used to
calculate how much solid ammonium sulfate (21.24 g) to add to it to yield 70% AS and thereby
precipitate the protein. The solid AS was added slowly to the supernatant while stirring at room
temperature (NO heat) and the pale yellow supernatant turned white-brownish as the AS was
dissolving. Once all the AS had dissolved, the supernatant was centrifuged at 10,000 xg for 30
minutes at 4ºC and the supernatant was discarded whereas the pellet was kept and dissolved in 80
mL of dialysis buffer/buffer A (for 2L: 25 mM TRIS-HCL pH 7.5 (6.055 g TRIS-HCl), 50 mM
KCl (7.456 g KCl), 2 mM DTT (4 mL 1M DTT), 1 mM EDTA (2 mL 1M EDTA)) and dialyzed
overnight at 4ºC through a 12 – 14 kDa dialysis bag.
Then, the dialyzed protein was centrifuged at 17,000 rpm for 30 minutes at 4ºC, and the
pellet was discarded. The supernatant was submitted to an ion exchange chromatography and
loaded onto a 30 mL Q-Sepharose column that was equilibrated with buffer B (low salt QSepharose buffer, 1 L: 25 mM TRIS-HCl pH 7.5 (3.03 g TRIS-HCl), 50 mM KCl (3.728 g KCl),
2 mM DTT (2 mL 1M DTT), 0.25 mM EDTA (250 μL 1M EDTA)) and ran about 300 mL gradient
with buffer C (high-salt Q-Sepharose buffer, 1 L: 25 mM TRIS-HCl pH 7.5 (3.03 g TRIS-HCl),
500 mM KCl (37.28 g KCl), 0.25 mM EDTA (250 μL 1M EDTA), 2 mM DTT (2 mL 1M DTT))
to 100 % C, at a flow rate of 5 mL/min and collected in 4 ml fractions that are shown by the brown
box (Figure 2.5). T7 RNA polymerase elutes up to 80% C as it is protein quantification dependent,
but it typically elutes between 30 – 60% C. Fractions 56-71 were pooled and dialyzed overnight
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in buffer D (4 L: 25 mM Hepes-KOH pH 7.5 (23.83 g Hepes), 75 mM KCl (22.369 g KCl), 2 mM
DTT (8 mL 1M DTT), 1 mM EDTA (4 mL 1M EDTA)); (an over concentrated protein will crash
out, therefore, 15 ml of the protein was added to 15 mL of buffer D and the mixture (cloudy) was
dialyzed against buffer D to avoid aggregation of the whole sample; the remainder of the sample,
17 mL was diluted in 17 mL of 65% buffer (buffer B + buffer C) that corresponded to the percent
of buffer C at which the protein was eluted off the column, the mixture (clear) was dialyzed in
buffer D overnight).

Figure 2.5: Ion exchange chromatography of T7 RNA polymerase on Q-Sepharose column,
showing the peak elution of the enzyme between 270 – 315 ml

The dialyzed protein was subsequently centrifuged at 17,000 rpm at 4ºC for 30 minutes
and the pellet was discarded. The supernatant was then subjected to a cation exchange
chromatography on a 30 mL SP-Sepharose FF column (Figure 2.6) that was equilibrated with
buffer E (low salt SP-Sepharose buffer, 1 L: 25 mM Hepes-KOH pH 7.5 (5.96 g Hepes), 25 mM
KCl (1.864 g KCl), 2 mM DTT (1 mL 1M DTT), 0.25 mM EDTA (0.25 mL 1M EDTA)) and
eluted in 4 ml fractions with about 300 mL gradient to 50% buffer F (high salt SP-Sepharose
buffer, 1 L: 25 mM Hepes-KOH pH 7.5 (5.96 g Hepes), 500 mM KCl (37.28 g KCl), 2 mM DTT
(1 mL 1M DTT), 0.25 mM EDTA (0.25 mL 1M EDTA)) when the absorbance was under 0.05 A
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at 280 nm. The fractions were pooled and the concentration at 280 nm was calculated using T7
RNA polymerase extinction coefficient, which is 141.36 mmol-1 cm-1. The protein was then diluted
to 1 mg/ml with cold storage buffer G and dialyzed overnight at 4ºC against 3L of the buffer G (3
L using DEPC treated water: 20 mM potassium phosphate (K2HPO4) buffer, pH 7.5 (10.45 g
K2HPO4), 0.1 mM DTT (300 μL DTT), 100 mM KCl (22.368 g KCl), 0.1 mM EDTA (300 μL
EDTA), 50 % (v/v) glycerol). The DEPC treated water was made by stirring 0.1% (v/v) solution
of DEPC in water overnight, before autoclaving for 30 minutes to destroy DEPC. The dialyzed
enzyme was diluted to a final concentration of 1 mg/mL using the cold storage buffer, aliquot, and
kept at -80ºC.

Figure 2.6: Cation exchange chromatography of T7 RNA polymerase on SP-Sepharose column,
depicting the elution peak of the enzyme, between 380 – 430 mL.

2.2.2 Synthesis of STR7 RNA
Top strand STR7 DNA was purified by mixing 200 µL of thawed top strand (IDT
85750802, MW 5466.6g/mole) with 200 µL of 2 X ficoll urea loading buffer (Table 2.6, appendix
A). The mixture was heated at 75ºC for 15 minutes and loaded on a 20% analytical polyacrylamide
gel (Table 2.7, appendix A) that was run at constant 13 Watts in 1X TBE buffer (Table 2.3.8) for
about three hours. The bottom strand STR7 DNA (IDT 276495871, MW 29,764.2 g/mol) was
purified using a mixture of 75 µL of 20 mg bottom strand DNA sample and 75 µL of 2X ficoll
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urea loading buffer, which was also heated at 75ºC for 15 minutes and loaded on a 20% analytical
polyacrylamide gel and run at 13 Watts for about 2.5 hours. At the end of the run, the gels were
visualized on a silica thin layer chromatography plate (TLC) with 254 nm UV lamp (Figure 2.7),
and the bands were cut out from the gels and submitted to electro-elution at 200 Volts in 0.5X
TBE buffer (Table 2.8, appendix A).

Figure 2.7: Purification gel of STR7 top strand

The electro-elution was performed using the Elutrap electrophoresis apparatus with
Whatman Elutrap BT1 and BT2 membranes in the chambers. BT2 membranes allow the passage
of nucleic acids while BT1 membranes do not. The nucleic acids migrated from the anode to the
cathode, where they were collected every hour. Prior to collecting the samples, the current was
paused, run in reverse for 20 seconds to allow any nucleic acids that might had been aggregated
onto the membrane to go into the solution, and the current was paused again for collection. The
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nucleic acids were removed between the BT1 and the BT2 membranes as 400 µL-samples into 2ml Eppendorf tubes and checked for absorbance at 260 nm with the Thermo Scientific NanoDrop
Lite. The process was repeated every hour until the absorbance was deemed no longer significant,
typically (0.1 – 0.2). Each sample was precipitated overnight with 40µL of 3M sodium acetate and
1320µL of cold absolute ethanol. The precipitated samples were centrifuged at 13,000 rpm at 4ºC
using the Eppendorf 5430R; the pellets were collected, pooled, and re-suspended in 400µL of deionized water to eliminate any EDTA and impurities. To the latter, 40µL of 3M Sodium Acetate
and 1320µL of cold absolute ethanol were added for re-precipitation followed by centrifugation
and the pellets were re-suspended in 300µL of de-ionized water, as the stocks of STR7 DNA and
stored in -20ºC freezer. The extinction coefficient of the newly made stock of top strand DNA was
found to be 182,500 L/ (mole*cm) from OligoAnalyzer 3.1 IDT and the concentration was
calculated from the absorbance taken with the UV spectrophotometer. As for the bottom strand
DNA, the extinction coefficient 911,300 L/ (mole*cm) was given on the package and the
concentration was determined using the absorbance obtained.
From the newly purified top and bottom strands of STR7 DNA, 8µM stocks of each were
made. The latter stocks and newly made transcription reagents (Tables 2.12 – 2.14, appendix A )
were tested against old reagents and optimized in MgCl2 (Figure 2.8) along with the new T7
RNAP (Figure 2.9), according to Louis small RNA recipe (Table 2.9, appendix A). T7 RNAP is
a single subunit bacteriophage that catalyzes the RNA synthesis reaction, which produces a white
precipitate, characteristic to RNA formation, and pyrophosphate (P Pi) as the byproduct. [28,29] The
residues D537 and D812 in its catalytic site had shown to be the drive for the binding of magnesium
ions (Mg2+) to the active center involved in the formation of the phosphodiester bond.

[28,30]

The

cofactor Mg2+ binds the PPi to form Mg2PPi. [29] It has been theorized that one Mg2+ acts as a
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nucleophile by favoring the formation of the hydroxide ion and binds the attacking hydroxyl while
the second Mg2+ stabilizes the transition state of the phosphodiester bond and aids in the exit of
the 3’hydroxide. [28,29]

Figure 2.8: Optimization of magnesium chloride: A) Standard 55 mM. B) Empty. C) 52.2 mM 5% less MgCl2. D) 49.5 mM - 10% less MgCl2. E) 46.8mM - 15% less MgCl2. F) 44 mM - 20%
less MgCl2. G) 41.2 mM - 25% less MgCl2.
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Figure 2.9: Optimization of the new T7 RNA polymerase: A) 52.25mM. B)
49.5 mM. C) 47 mM. D) 44 mM. E) 41 mM. F) Standard. G) 15% more MgCl
2. H) 25% more MgCl2

Once the optimal MgCl2 concentration was determined, a large- 2 mL transcription was
made according to the protocol devised previously in Leeper’s group (Table 2.9, appendix A).
An equal volume- 2 mL of 2 X ficoll loading buffer was added to the sample and the mixture was
heated for three minutes and then loaded onto a preparative 12% polyacrylamide gel (Table 2.10,
appendix A). The gel ran between 17 - 19 hours (12 hours at 20W and about 7 hours at 4W), after
which the RNA band was visualized on a thin layer chromatography (TLC) plate with UV lamp
and cut out from the gel (Figure 2.10). The RNA band was submitted to electro-elution and
precipitated in the same manner as the DNA bands. The RNA sample was then loaded onto a size
exclusion chromatography column GE Hiload 16/600 Superdex 75 pg (Figure 2.11), which was
equilibrated with 300 ml of SEC buffer. Loading and elution were conducted at a rate of
0.6mL/min and about 200 µL fractions were manually collected into autoclaved 1.5 ml Eppendorf
tubes to avoid RNase as RNA sticks to glass and the fraction collecting glass-tubes are re-used for
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protein collection. Some samples were lyophilized. Absorbance at 260 nm was taken for each
sample to determine the concentration using STR7 extinction coefficient, 984251.9685L/mol*cm;
the samples were subsequently stored in the -80ºC freezer.
2.2.3 Lyophilization
The precipitated RNA from electro elution was spun; the supernatant was discarded and
the pellet was kept and re-suspended in about 200 µL of deionized sterile filtered water; 50 µL of
the re-suspended STR7 was taken and subjected to “snap cool”, meaning that the RNA was heated
for three minutes (here at 89ºC) and was quickly cooled on ice for five to ten minutes (here ten
minutes) to allow STR7 to refold, thereby, minimizing the aggregate shoulder that would come off
during the SEC run. Then, the “snap cool” STR7 was loaded onto the SEC column with low salt
SEC buffer, 0.1 X SEC buffer (Table 2.5, appendix A). The peak-fractions obtained from the
SEC were pooled together into 15 ml falcon tubes and frozen at -80⁰C for three to four hours. After
three hours, the samples were removed from -80⁰C freezer and placed in a 600-mL LABCONCO
glass flask with a top. The top for the falcon tube was removed and replaced with parafilm that
had multiple small holes made with a clean needle, so that moisture could be evaporated during
lyophilization. The container was then attached to the lyophilizer vacuum and the samples were
left on for twenty-four hours or until they were completely dry with only a white snow flake-like
powder seen in the tubes. The powder was re-suspended in one hundred-and-fifty microliters of
deionized filtered sterile water to give a more concentrated sample for SEC-SAXS experiments.
Throughout the text, the “snap cool” STR7 RNA will be referred to as the “treated” STR7 RNA
and the precipitated and re-suspended STR7 RNA from direct electroelution will be referred to as
the “untreated” STR7 RNA.
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RNA band

Xylene cyanol

Figure 2.10: 12% preparative polyacrylamide gel showing the RNA band and
the xylene cyanol dye band. The bromophenol blue band ran off the gel.

Figure 2.11: Size exclusion chromatography of STR7, showing the elution of the RNA.
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2.3 SAXS study
2.3.1 X-ray Scattering measurements
The purified biomolecules were used to assemble the complexes (Table 2.14) on the
synchrotron site. The small angle X-ray scattering data were collected on the Life Science X-ray
Scattering (LiX) beamline at the National Synchrotron Light Source II (NSLS II) at Brookhaven
National Laboratory (BNL). In-line SEC-SAXS was performed. The high performance liquid
chromatography (HPLC) system was enclosed in a rack and put in close distance to the solution
scattering enclosure to minimize peak broadening. The HPLC X-ray data collection was divided
into two parts: the first part was on Windows where the HPLC parameters execution and sample
elution were set. The second part was on the Linux machine, where data collection was
synchronized (a signal was sent to the HPLC machine to alert of the readiness of the beamline for
data acquisition - pretreatment and the running of the sample, a second signal sent for the beamline
data collection) The beam had an energy of 11.98 keV and the X-rays were focused by reflecting
through Primary Focusing KB mirrors and compound reflective lenses for secondary focusing.
The samples were put in PCR tubes (put on a metal sample-holder) and ran at room temperature
using SD75 Increase, GL 5/150 column for SEC at a flow rate of 0.35 mL/min with 1X SEC buffer
(Table 2.5), then submitted to SAXS. Each sample data was typically collected between 10 to 15
minutes. All of the samples were run in the same buffer. Three detectors were utilized to
simultaneously record the scattering data: ultraviolet (UV) detector and refractive index diffraction
(RID) detector. Two of the scattering detectors were for wide-angle X-ray scattering (WAXS) and
one was for SAXS.
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Table 2.14: Concentrations and volumes for SAXS experiment samples
Sample
1.97mgSTR7 (snap cool)
1.97mgSTR7 - 3.5mgSHARP2
3.50mgSHARP2
5.86mgSHARP2
5.07mgSTR7
7.00mgSTR7 - 5.86mgSHARP2
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Volume
70µL
35µL RNA : 35µL SHARP2
70µL
70µL
40µL
35µL RNA : 35µL SHARP2

CHAPTER 3. RESULTS AND DISCUSSION
3.1 Results
These data were collected through in-house Python based macros called Bluesky and saved
as .h5 files. The files were processed in Jupyter notebook, where the buffer subtraction was
performed via singular value decomposition (SVD) and the Guinier approximation curve along
with the radius of gyration were obtained for the free STR7, SHARP2, and STR7-SHARP2
complex. The SVD is a method used to find the components within the background by first
excluding the peaks that contain the scattering data for SVD analysis on the background. SVD
uses matrixes: the first data matrix A is transformed into a second matrix B by a series of
Householder transformations that are linear transformations, then, a specially modified QR
(decomposition of a matrix A into a product, A= QR) algorithm is applied to compute the singular
value decomposition of B.

[31]

The analysis yields a plot that shows the polynomial fit of the

background components outside the excluded frames. The X-ray wavelength was 1.03 Angstrom
and the Bragg angle was 9.50o. The .dat files acquired from the data processing in the Jupyter
notebook were transferred into primus

[31]

in ATSAS 2.8.4

[32]

to get the particle distance

distribution curve p(r), the Kratky plot, and multiple parameters including the maximum distance
(Dmax) of the molecule. The values determined in primus were used in the ab initio method to build
the atom shape and consequently fit the structure into the envelopes.
3.1.1 Guinier plots
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Figure 3.1: Guinier plots of the biomolecules. A) “Untreated” free STR7 RNA. B)
“Treated” free STR7 RNA. C) 3.5 mg/mL SHARP2 protein. D) 5.86 mg/mL
SHARP2 protein. E) “Treated” STR7 RNA-SHARP2 complex. F) “Untreated” STR7
RNA-SHARP2 complex. Adaptation of screenshots pictures from Jupyter notebook.
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The scattering of the buffer was subtracted from that of the buffer + sample, to yield the
scattering data for the Guinier curve of the sample. The experiment was conducted by
incorporating HPLC. The HPLC was in-line with SAXS and the SAXS detectors were integrated
as other channels in the traditional HPLC for the analysis of the biomolecules. The scans of the
SAXS scattering of the eluate coming from the column were taken in real time, with the elution
time on the x-axis and the intensity on the y-axis. For example, in Figure 3.2A, the blue curve
represented the total raw X-ray scattering over all angles of the “treated” free STR7 RNA while
the orange curve represented the UV/VIS trace. The box under the curve depicted the 2D heat map
of the SAXS profile, with the elution time on the x-axis and the scattering angles, q on the y-axis.
The background curve before and after the peak was not even, therefore the buffer subtraction was
performed using a single value decomposition (SVD) to find the background components. The
range for the background was selected to exclude the elution peak. The SVD analysis yielded the
curve in Figure 3.2B, where the background curve before and after the peak was even; the 2D heat
map showed the residual signals from the bio-analysis that can stand out from the noise. The
yellow dense dots represented the intensity of the scattering. The data analysis was only performed
on frames (shown by the green box around the peak) for the parts of the molecule that we thought
were representative of the sample. All the subsequent analysis were data from the selected frames.
The polynomial from the SVD analysis was around 4 for most of the data, except for the protein
data, where the polynomial was 16.

32

A

B

Figure 3.2: Left: X-ray and UV/VIS raw data curves and the 2D heat map of SAXS profile
(bottom) of “treated” free STR7. Right: Data of “treated” free STR7 after buffer subtraction (top:
curve; bottom: 2D heat map of SAXS profile).

The Guinier approximation states that regardless of a particle shape, at small angle, q, the
intensity is dependent of the particle’s radius of gyration. Guinier region shows the quality of the
sample in terms of aggregation and/or inter-particle interaction. An indication of aggregation is
reflected by a non-linear plot at low q with an upward curve and a repulsion is indicated by a nonlinear plot with a downward curve. [19] The displacements, q, of the X-ray scattering were averaged
to give 1D data from the 2D data as seen illustrated by the Guinier curves in Figure 3.1. The red
points on the fitted curves were not part of the fitting; they were inserted by the program)
The curves showed the free STR7 RNA, free SHARP2 at different concentrations, and the
“treated” STR7 RNA-SHARP2 and the “untreated” STR7 RNA-SHARP2 complexes. The orange
line within the graph was fitted into the low-q region of the Guinier curve, which was represented
by the blue curve. The intensity I of the X-ray scattering was plotted against the square of the
averages of the magnitude of the vector displacement q (Å-2). For each sample, the curve showed
a good and linear fit for the Guinier approximation at small angles, meaning that there were no
aggregations in the samples. The extrapolation to zero angle gave an intensity of I (0) = 11.72+/-
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0.028, and a radius of gyration, Rg = 34.58+/-6.65 Å for the free “treated” STR7 RNA. The free
“untreated” STR7 RNA intensity was I (0) = 14.41+/-0.012 and Rg = 31.43+/-1.36 Å. The radius
of gyration Rg was derived from the slope of the fitted line and the intensity I (0) was derived from
the vertical intercept. The intensity I (0) = 1.96+/-0.0052 and the radius of gyration R g = 15.48+/0.25 Å for 3.5 mg/mL of 15N SHARP2 in 3.1C and I (0) = 2.51+/-0.016 and Rg = 15.19+/-0.35 Å
for 5.86 mg/ml of 15N SHARP2 in 3.1D. For the “treated” STR7 RNA- SHARP2 complex in 3.1E,
the intensity I and the radius of gyration Rg yielded 4.55+/-0.027 and 30.67+/-9.00 Å, respectively
and I (0) = 18.14+/-0.023 and Rg = 32.04+/-0.25 Å for the “untreated” STR7 RNA- SHARP2
complex in 3.1F.

Table 3.1: Rg, Dmax, and I(0) of the biomolecules

Sample

Rg (Å)

Dmax (Å)

I(0)

“Treated” free STR7 RNA

34.58+/-6.65

94.26

11.72+/-0.028

“Treated” STR7 RNA-SHARP2 complex

30.67.+/-9.00

78.87

4.55+/-0.027

“Untreated” free STR7 RNA

31.43+/-1.36

87.20

14.41+/-0.012

“Untreated” STR7 RNA-SHARP2 complex

32.04+/-0.25

98.43

18.14+/-0.023
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3.1.2 Kratky plots
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Figure 3.3: Kratky plots of the biomolecules. A) “Treated” free STR7 RNA. B) “Treated”
STR7 RNA-SHARP2 complex. C) “Untreated” free STR7 RNA. D) “Untreated” STR7
RNA-SHARP2 complex. Adapted screenshots of processed data from primusqt

The data file obtained from the Guinier processing was again uploaded into
primus/primusqt to give the Kratky curves. Through Kratky plot, where flexibility, unfolding or a
conformational change is revealed, structural changes can be monitor by SAXS in a semi
quantitative way.

[24]

The curve of an unfolding molecule shows a continuously extended curve
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that do not have a down turn towards the x-axis, compare to the curve of a folded molecule. The
Kratky curves as seen in Figure 3.3 showed the plots of I*s2 on the y-axis vs. s on the x-axis and
revealed the folded states of the each of the molecules (s and q are interchangeable).
3.1.3 Particle distance distribution curves
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Figure 3.4: Particle distance distribution, p(r). A) “Treated” free STR7 RNA. B) “Treated”
STR7 RNA-SHARP2 complex. C) “Untreated” free STR7 RNA. D) “Untreated” STR7 RNASHARP2 complex. Adaptation of the screenshots of the processed data using primusqt
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p(r)

SHARP2

(Å)

r, nm
Figure 3.5: Ideal p(r)-distribution of different model structures incorporated with the p(r)distribution of the RRM 2 domain of SHARP. Adapted from Svergun & Koch, Rep. Prog.
Phys, 2003.

The particle distance distribution of the samples was processed using primusqt in ATSAS
2.8.4. From the files acquired from the Guinier plot processing, the p(r)-distribution curves of the
particles were generated. The SAXS profile I(q) was Fourier transformed into the p(r)-distribution,
where the data measured in reciprocal space (Å-1) was transformed to real space (Å) as shown in
Figure 3.4.

[20-24]

The p(r)-distribution is a smooth curve of the histogram representing all the

possible electron-pair distances, r, within each molecule. The result from the p(r)-distribution was
an estimated maximum distance, Dmax, of the particle. The particle distance distribution assured
that Dmax was correctly chosen as the predicted distribution should be smooth with minimal
oscillations near Dmax. [22]. The Dmax obtained were 94.26 Å and 87.20 Å for the free “treated” and
37

the free “untreated” STR7 RNA, respectively. The Dmax was 78.87 Å for the “treated” STR7 RNASHARP2 complex and 98.43 Å for the “untreated” STR7 RNA-SHARP2 complex. Control p(r)
of the free SHARP2 protein was also processed (see appendix C) and the Dmax was found to be
48.57 Å.
3.1.4 Super-imposed curves of free STR7 RNA and STR7 RNA-SHARP2 complex

,Å
Dmax
Figure 3.6: Overlay of the particle distance distribution of “treated” STR7 RNA with and
without SHARP2
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,Å

Dmax

Figure 3.7: Overlay of the particle distance distribution of the “untreated” STR7 RNA in the
presence/absence of SHARP2

The super-imposed curves of STR7 RNA in the presence/absence of SHARP2 protein are
shown in Figures 3.6 and 3.7. The plots were obtained from the .out files acquired from the p(r)
processing in primusqt. The graphs illustrated the changes that occurred once the STR7 RNA was
bound by SHARP2 protein. The “untreated” free and “treated” free STR7 RNA were plotted on
the left y-axis, whereas the STR7 RNA-SHARP2 complexes were plotted on the right y-axis. The
Dmax obtained were 94.26 Å for the “treated” free STR7 RNA and 78.87 Å for the “treated” STR7
RNA- SHARP2 complex. As for the “untreated” free STR7 RNA and the “untreated” STR7 RNASHARP2 complex, Dmax were 87.20 Å and 98.43 Å, respectively.
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3.1.5 Ab initio beads models

“Untreated” free STR7
RNA

“Treated” free STR7 RNA

“Untreated” free STR7
RNA

“Untreated” STR7 RNASHARP2 complex

“Treated” free
RNA

STR7

“Treated” STR7 RNASHARP2 complex

“Untreated” STR7 RNASHARP2 complex

“Treated” STR7 RNASHARP2 complex

Overlay

Overlay

Overlay

Overlay

Figure 3.8: Ab initio beads models of the free and bound “treated” and “untreated” STR7
RNA, and the overlay biomolecules. Adapted screenshots of processed data from primusqt
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In the ab initio shape determination method, the particle is illustrated as a collection of
compacted beads (dummy atoms) packed in a search volume. From the one-dimensional scattering
data, the ab initio shape analysis seeks to get the three-dimensional structure
low-resolution (1-2 nm) shape of the molecule of interest.

[20]

[33]

and provides a

In this method, an important

limitation required for low-resolution ab initio modeling is that all the dummy atoms representing
the molecule must be interconnected to make a single body in the final model. [33] Because different
initial random models are utilized to obtain the final model, most of the time ten to twenty ab initio
runs have to be performed, then averaged to obtain the distinctiveness of the solution and yield the
most obvious shape features.

[20,33]

In this study, fifteen (15) ab initio runs were conducted for

each: the “treated” and “untreated” STR7 RNA, “treated” STR7 RNA-SHARP2 complex, and
“untreated” STR7 RNA-SHARP2 complex. There was no symmetry imposed on the molecules.
The ab initio beads models were processed in primusqt using the .out files from the p(r) output in
GNOM. The ab initio method utilized DAMMIF, which is an ab initio tool to construct the model
to give a scattering configuration that fits the experimental data. [16,33] Then, DAMMAVER to align
the ab initio models to build an average model, followed by DAMMIN to refined and restore the
model to yield ab initio low resolution shape of the particles in subjective directions in the solution
from SAXS.

[18,20,22]

Figure 3.8 showed the free STR7, the STR7-SHARP2 complexes for each

condition, and their superimposition.
3.2 Discussion
STR7 RNA and SHARP2 protein were submitted to SEC-SAXS as free solutions and then
as mixed samples to produce complexes. To check for the quality of each sample, the UV/X-ray
raw SEC-SAXS data was processed to obtain the Guinier plots (Figure 3.1). The Guinier region,
which is the region at low q that illustrates the presence/absence of aggregations and/or inter41

particle interactions showed that SHARP2 had low intensity at zero angle (Figure 3.1C and 3.1D),
however, the fitted line into the SAXS profile was good. The reduction in the intensity can be due
to the pH and/or ionic strength of the SEC buffer. The pH of the SEC buffer used was 7.6, which
was less than one (1) unit from the pI of SHARP2 protein, which is 6.71. A buffer with a good
ionic strength helps prevent non-specific interactions between the protein and the column. But, the
salt concentration of the SEC buffer was 100 mM, which was lower than the average salt
concentration for the SEC buffer of the protein, usually about 150 mM or higher. These two factors
caused some disturbances in SHARP2 at very low q. However, STR7 RNA and STR7 RNASHARP2 complex were very stable in the SEC buffer because RNA is stable in pH 6-8; RNA is
more stable in acidic pH or near neutral pH and it is destabilized above pH 8 because of its chemical
structure. [34-38] On the other hand, increasing the ionic strength would had rendered STR7 RNASHARP2 complex unstable. Therefore, it was a challenge in accommodating all the biomolecules
in this study. Nonetheless, there were no aggregations in the protein and the RNA, which was the
molecule of interest in this investigation.
The Guinier plots of “treated” and “untreated” STR7 (Figure 3.1A and 3.1B) also showed
no aggregations and/or inter-particle interactions in the samples. However, an increase in the
radius of gyration of the “treated” free STR7 (Rg = 34.58+/-6.65 Å) was seen compared to that of
the “untreated” free STR7 (Rg = 31.43+/-1.36 Å), meaning that the molecule has expanded and/or
re-shaped. According to Svergun et al., the Rg given by a scattering experiment is an initial
indication of the density of the molecule and the larger the Rg, the more unsymmetrical the shape.
In the case of X-ray scattering, most single-constituent macromolecules (proteins, nucleic acids)
can be considered to have almost uniform electron density and the R g is linked to the geometrical
form of the molecule. Actual macromolecules do not have uniform electron density, unless their
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molecular masses were greater than 30 kDa and a reasonable estimate can be obtained with a
proper subtraction.

[15,16]

The Guinier plots of the “treated” STR7 RNA-SHARP2 and the

“untreated” STR7 RNA-SHARP2 complexes revealed the absence of aggregation, although, at
very small angle, there was an upturn in their curves, signifying inter-particle interaction, which
was understandable as these were complexes and there was some interactions between the
molecules. The radius of gyration of the “treated” and “untreated” STR7 RNA in complex with
SHARP2 were 30.67+/-9.00 Å and 32.04+/-0.25 Å, respectively, demonstrating that the
“untreated” STR7 RNA-SHARP2 complex was more extended than the “treated” STR7 RNASHARP2 complex and different in their electron density.
Further analyses to yield the Kratky plots (Figure 3.3) and the particle distance
distribution, p(r) curves (Figure 3.4), were performed to evaluate the folded/unfolded state of the
biomolecules and the maximum distance and the shape of STR7 RNA to SHARP2. The Kratky
curves showed that the free and the complexed molecules were well folded, with the protein having
a projecting peak at low angles, and not an unceasing rise in s2I (s) with s.

[15]

However, all the

molecules were not folded in the same way. The folded state of STRA7 RNA was exhibited by the
parabolic convergence of the data at high s, a characteristic that satisfies the constant Q, where the
area under the curve approaches a fixed value and allows the calculation of the hydrated volume
(Porod volume) of the particle. This is untrue for an unfolded molecule, as a definite area in a
Kratky plot is not captured by its scattering plot.

[22]

The bumpy p(r)-distribution curves of the

biomolecules revealed that the molecules were not perfect solid sphere. Figure 3.5 showed the
ideal p(r)-distribution from different model structures; for example, the globular RRM2 domain
of SHARP displayed a standard globular p(r)-distribution shape. There was not much difference
between the shape of the p(r)-distribution curves of the “treated” free and the “untreated” free
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STR7 (Figure 3.4A and 3.4C). But, a greater and intriguing change in the form of the curve and
a reduction in the maximum dimension of the “treated” free STR7 was seen when it was bound to
SHARP2 as well as a reduction in its radius of gyration, suggesting that the center of mass changed
or the molecule was compacted. This conformational change could also suggest that the binding
of SHARP2 was shape-selective and STR7 RNA is very flexible. This change could also have
suggested that STR7 could adapt to different conditions to accommodate SHARP2 binding.
The Dmax for the “treated” STR7-SHARP2 complex decreased to 78.87 Å from 94.26 Å for
the “treated” free STR7 and the radius of gyration changed from Rg = 34.58+/-6.65 for the free
“treated’ STR7 to Rg = 30.67+/-9.00 for the “treated” STR7-SHARP2 complex. An overlay of the
p(r) curves (Figure 3.6) gave a better visual of the shape of the p(r)-distribution curve: the
“treated” STR7-SHARP2 complex converged to a more rounded figure, from the extended state
of the free STR7, which is a characteristic of RNA. In the case of the “untreated” STR7 (Figure
3.7), an increase in the radius of gyration of the complex STR7-SHARP2 (Rg = 32.04+/-0.25 Å)
had been noticed compared to that of the “untreated” free STR7 (Rg = 31.43+/-1.36 Å) as well as
an increase in the Dmax of the “untreated” STR7-SHARP2 complex (Dmax = 98.43) compared to
that of the “untreated” free STR7 RNA (D max = 87.20), showing that the particle had increased in
size and the binding of SHARP2 to STR7 did increase the radius of gyration of STR7, although,
there was not a huge noticeable alteration in the shape of the p(r) curve.
The dramatic change in the configuration of STR7 was further observed in the ab initio
beads models, supporting our hypothesis that the binding of SHARP2 to STR7 RNA triggered a
conformational change in STR7. The “untreated” STR7-SHARP2 complex was still a little
elongated compared to the free “untreated” STR7, whereas the “treated” STR7-SHARP2
complex revealed a completely different shape compared to the free “treated” STR7. Moreover,
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the superimposition of the “treated” STR7-SHARP2 complex with the “untreated” STR7SHARP2 complex showed two completely different conformations, therefore, opening the door
to multiple questions.
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CHAPTER 4. CONCLUSION
The investigation was conducted using SEC-SAXS and the biomolecules under study were
found to be free of aggregations. The “treated” free and “untreated” free STR7 RNA have shown
subtle difference in their shapes and their radius of gyration, Rg were 34.58+/-6.65 Å and 31.43+/1.36 Å, respectively. But, a bigger change was observed in the configuration of the “treated” STR7
RNA once it was bound to SHARP2 as well as a reduction in the Dmax and the Rg. The Dmax for the
“treated” STR7 RNA-SHARP2 complex was 78.87 Å while the Dmax for the free “treated” STR7
RNA was 94.26 Å and the radius of gyration had changed from 34.58+/-6.65 Å for the “treated’
free STR7 RNA to 30.67+/-9.00 Å for the “treated” STR7 RNA-SHARP2 complex. In the case of
the “untreated” STR7 RNA, there was not a substantial change in the configuration of STR7 RNA
once it was bound to SHARP2, although, the radius of gyration of the “untreated” free STR7 RNA
had increased from 31.43+/-1.36 Å to 32.04+/-0.25 Å in the bound state and the Dmax had also
augmented from 87.20 Å to 98.43 Å when STR7 RNA was bound by SHARP2. The binding of
SHARP2 to the “treated” STR7 RNA had accounted for changes in the radius of gyration, the
Dmax, and the configuration of STR7 RNA, while the binding of SHARP2 to the “untreated” STR7
RNA had caused an increased in the radius of gyration and the Dmax of STR7 RNA.
This intriguing change in the configuration of “treated” STR7 RNA in the bound state leads
to the need for further investigations to better understand how and where SHARP2 recognizes
STR7 RNA and thereby, give a comprehensive binding mechanism of SRA RNA and SHARP2
and possibly a molecular mechanism of lncRNAs. In light of this dramatic change in the
configuration of STR7 RNA, is it possible that STR7 RNA has more than one binding sites that
became more exposed when the RNA was submitted to a different condition? Does SHARP2
protein have a preference for a certain folding state of STR7 RNA? Does STR7 RNA have a
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memory mechanism that allows it to remember its refolding state in the presence of SHARP2
because the free “treated” and “untreated” STR7 RNA had almost identical shape? Where did the
change occurr?
SAXS is a good technique that gave the overall shape, size, and other parameters of the
biomolecules. In this study, the weight of STR7 RNA is about two-and-half times the weight of
SHARP2, meaning that STR7 RNA is heavier, and heavier atoms have more electrons. Since the
X-ray scattering and the absorption are sensitive to electron density,

[20]

the RNA is therefore

expected to contribute more to the scattering of the sample. The data obtained showed that the free
“treated” and “untreated” RNA and the bound RNA had greater scattering than the protein by
itself, but the scattering was from both molecules in the case of the complexes. The experiment
was not designed in a way to show how much each molecule had contributed to the scattering and
the bead models obtained did not account for the part of each molecule that actually participated
in the binding.
RNA/protein complex makes it difficult to understand how each species behaves when it
comes to modeling because of the scattering contribution from both molecules. The SAXS analysis
can be improved by conducting a contrast variation/matching technique with high concentrations
of sucrose at LiX at Brookhaven National Laboratory to mask the protein or the RNA and thereby,
obtain scattering information from either just the RNA or the protein, but in the bound state,
provided that they are in the true conformations. Performing the technique at different sucrose
concentrations starting with 50 percent (w/v) sucrose and using different concentrations of protein
and RNA will help explore various conditions for better scattering. Pollack et al have successfully
used the contrast variation with time-resolve SAXS to determine intermediate structures of protein
and DNA components of nucleosome core particles (NCPs) during salt induced disassembly. In
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their study, they blanked the protein by adding 50% (w/v) sucrose to the solvent to match the
solvent’s electron density to that of the lower density of the protein, making the protein
unnoticeable above the background and allowing only the DNA to account for the scattering.

[39]

Contrast comes from the difference in electron density, therefore, by adding small molecules of
sucrose to the solvent, it increased the density of the solvent until that density matched that of the
protein and blanked the protein.

[39]

The contrast matching can help see the actual scattering

contribution from the RNA, the conformation changes, and possibly where the binding occurred.
However, this method will require an improvement of the current final concentration of the STR7
RNA from the SEC column since static SAXS will be used and the buffer has to be perfectly
matched, meaning that lyophilization cannot be performed as it will alter the buffer. LiX requires
that the samples should be concentrated as much as possible, at least 1 mg/mL; dilution can be
made on site. At present, loading about 50 microliters of 10.5 mg/mL of STR7 RNA yields a high
concentration of about 0.4 mg/mL from the column. The concentration of the crude STR7 RNA
was increased to about 12 mg/mL, however there were no significant improvements in the
concentration of the samples after SEC. Different concentrations can be tested on the SEC column,
but the column should not be overloaded; or an appropriate SEC column shorter than the current
GE Hiload 16/600 Superdex 75 pg column can be used, just for the RNA to avoid too much dilution
of the samples.
Another approach to improve the SAXS analysis would be neutron scattering at Oak
Ridge National Laboratory. SANS is a small angle neutron scattering method, where the
neutrons interact with the nucleus. The scattering is related to the nuclear scattering density, the
atomic number, and it is sensitive to the sample’s isotopic composition.

[20]

The sample does not

undergo radiation damage in SANS, however, more sample is needed compared to SAXS. In a
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SANS experiment, the contrast variation is very powerful as the neutron contrast can be
manipulated/adjusted by isotopic substitution without the need of significant chemical changes to
the sample. [11,40] The general low-resolution structure, in addition to the 3-D conformations of
the macromolecular constituents of the complexes as well as the higher-order complexes can be
obtained from the data.[40] Sattler et al in their analysis of a ternary protein-RNA complex using
NMR, SAXS, and SANS were able to use the contrast variation in SANS to solve remaining
structural ambiguities in the protein-protein-RNA complex involving two RRMs, where
ambiguous information was obtained for the protein-protein interaction. [11] The SANS
measurements performed on the samples of the ternary complex with subunit-specifically
deuterated at different percentages of D2O helped distinguish between structures and allowed the
identification of a single cluster. [11] This method can be applied to STR7 RNA-SHARP2
complex that only has one protein, and it can help determine STR7 RNA-SHARP2 contacts that
are not clearly seen with the current study. Determining those interactions can help clarify the
binding mechanism of STR7 RNA and SHARP2 and consequently the binding mechanism of
SRA RNA and SHARP2. Either SANS and/or sucrose contrast variation will help clarify the
current models and answer some of the questions.
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Appendix A
Buffers and gel recipes
Table 2.1: Minimal salts media (M9 media)

1 L M9 media

2 L M9 media

Dissolve first:
Na2HPO4

6.0 g

12.0 g

KH2PO4

3.0 g

6.0 g

NaCl

0.5 g

1.0 g

Then add one at a time:
40 mg/mL Thiamine-HCl

40 mg

80 mg

1 M MgSO4

10. ml

2.0 mL

1 M CaCl2

0.2 ml

0.4 mL

Antibiotic

1.0 ml

2.0 mL

Trace elements

10.0 ml

20.0 mL

Sterile filter, then add:
NH4Cl

0.5 g

1.0 g

Dextrose

2.0 g

4.0 g

Table 2.2: Buffer A
Buffer A
20 mM KHPO4, pH 7.6
200 mM KCl
2 mM DTT
20 mM imidazole
Add DI water, adjust pH to 7.6 using 6 M KOH. Finally, adjust the volume with DI water to the desired
volume.

Table 2.3: Buffer B
Buffer B
20 mM KHPO4, pH 7.6
200 mM KCl
2 mM DTT
400 mM imidazole
Add DI water, adjust pH to 7.6 using 6 M HCl. Finally, adjust the volume with DI water to the desired
volume.
Table 2.4: Dialysis buffer
Dialysis buffer
20 mM KHPO4, pH 7.6
200 mM KCl
2 mM DTT
Add DI water, adjust pH to 7.6 using 6 M KOH. Finally, adjust the volume with DI water to the desired
volume.
Table 2.5: SEC buffer
1 X (1 L) SEC buffer
50 mM NaHPO4, pH 7.6
100 mM NaCl
Add DI water, adjust pH to 7.6 using 6 M KOH.
Finally, adjust the volume with DI water to the desired
volume.

0.1 X (1 L) SEC buffer
Mix,
100 mL of 1 X SEC buffer + 900 mL ddH2O

Table 2.6: 2 X ficoll urea loading buffer
2 X ficoll urea loading buffer
0.5 Mm Tris-HCl, pH 7.5
0.5 mM EDTA
Urea
Ficoll 400
1% bromophenol blue and/or xylene cyanol
Adjust volume to 50 ml and store at room temperature

1.0 ml
0.1 ml
18 g
7.5 g
1.25 ml

Table 2.7: 20% analytical polyacrylamide gel
40 mL, 20% analytical
polyacrylamide gel
Urea
16.8 g
10 X TBE buffer

4 ml

40 % PAGE (19 acrylamide :
1 bis-acrylamide)

20 ml

50 mL, 20% analytical polyacrylamide gel
Urea

21 g

10 X TBE buffer

5 mL

40 % PAGE (19
25 mL
acrylamide : 1 bisacrylamide)
Dissolve completely in a 150 mL beaker + stir bar at low heat, then add:
10% w/v APS
240 µL
10% w/v APS
300 µL
Stir, then add:
TEMED

24 µL

TEMED

30 µL

Stir quickly and pour. Use 2 mm spacer, 1-well comb.

Table 2.8: Tris-Borate-EDTA (TBE) buffer
10 X TBE (500 mL)
54 g tris base
27.5 g boric acid
4.6 g Na2EDTA
Add dH2O to adjust to 500
mL, autoclave, and store at
room temperature

1 X TBE (1 L)
Mix,
100 mL of 10 X TBE +
900 mL dH2O

0.5 X TBE (1 L)
Mix,
50 mL of 10 X TBE + 950
mL dH2O

Table 2.9: Louis small RNA protocol
Ingredients

20 µL sample (44 2 mL sample (44
mM MgCl2) for
mM MgCl2) for
analytical gel
preparative gel
8 µM top strand STR7 DNA
2 µL
200 µL
8 µM bottom strand STR7 DNA
2 µL
200 µL
MgCl2
1.1 µL
88 µL
Heat anneal, temperature (90ºC for 30 – 60 seconds); cool to room temperature
Add:
100 Mm ATP
1.6 µL
160 µL
100 Mm CTP
1.6 µL
160 µL
100 mm GTP
1.6 µL
160 µL
100 MM UTP
1.6 µL
160 µL
20 X buffer
1 µL
100 µL
Polyethylene glycol (40% w/v)
4 µL
400 µL
DI H2O
1.5 µL
172 µL
Finally, add T7 polymerase
2 µL
200 µL
Heat at 37ºC for 2 hours, then quench the reaction with 170 µL of 0.5 M EDTA

Table 2.10: Preparative polyacrylamide gels
20% polyacrylamide gel, 150 mL
12% polyacrylamide gel, 150 mL
40% PAGE (19 acrylamide : 1
75 mL
40% PAGE (19 acrylamide : 1
45 mL
bis-acrylamide)
bis-acrylamide)
Urea
63 g
Urea
63 g
10 X TBE
15 mL
10 X TBE
15 mL
Stir at low heat until the urea dissolves, then add:
10% APS
900 µL
10% APS
900 µL
Volume with DI filtered sterile H2O to about 150 mL, stir, then add:
TEMED
90 µL
TEMED
90 µL
Stir and pour
Use 2 mm spacer, 1-well comb

Table 2.11: 20 X transcription buffer
20 X transcription buffer, 100 mL
Ingredients
Volume/mass
Weigh Tris or Trizma into a 250 mL beaker
9.7 g
Add DI H2O and stir until dissolved
50 mL
pH the solution to pH 8.0 using 2M HCl
Add spermidine and stir until dissolved
0.29 g
Prepare a 10% triton X-100 solution by adding:
In a 15 mL falcon tube, add
9 mL DI H2O
1 ml of triton X-100
Agitate to mix
Add 10% solution triton X-100 to the beaker
2 mL
containing the tris-HCl and spermidine
Finally, add to the beaker 1M DTT
10 mL
Top up the volume of the solution to 100 mL with DI H2O
Finally, aliquot into 1.5 mL Eppendorf tubes (500µL each); store all in -20ºC freezer. Do not
freeze/thaw each aliquot more than 2 times
Table 2.12: 40% (w/v) polyethylene glycol (PEG) and 10% (w/v) ammonium persulfate (APS)
40% (w/v) PEG
Weigh 4 g PEG (avg. mol. wt. 8000) into 15 mL
falcon tube
Add 4 mL of DI H2O and sonicate until dissolved
Volume to 10 mL with DI H2O and invert to mix
Filter through 0.22 µm syringe filter and aliquot 1
mL/Eppendorf tube
Store in -20ºC freezer

10% (w/v) APS
Weigh 0.1 g APS into 1.5 mL Eppendorf
tube
Add 900 µL of DI H2O and mix to
dissolve
Store in -20ºC freezer

Table 2.13: Nucleosides triphosphates
Nucleosides, 100 mM stock solution, 5 mL
ATP Pharmacia, prod#27-1006, FW=551.1
Weigh 276 mg ATP in about 4.5 mL of sterile filtered water
pH adjust to 7.0 with 6M NaOH
Finally volume to 5.0 mL
Filter through 0.22 µm and aliquot about 200µL into Eppendorf tubes
CTP Cat# 00095; Lot#001237-31612, MW=527.15
Weigh 264 mg CTP in approximately 4.5 mL of sterile filtered water
pH adjust to 7.0 with 6M NaOH (about 115 µL)
Finally volume to 5.0 mL
Filter through 0.22 µm and aliquot about 200µL into Eppendorf tubes
GTP Cat# 00348; lot# 002363-131215 chem impex MW=567.15
Weigh 284 mg GTP in approximately 4.5 mL of sterile filtered water
pH adjust to 7.0 with 6M NaOH (about 60 µL)
Finally volume to 5.0 mL
Filter through 0.22 µm and aliquot about 200µL into Eppendorf tubes
UTP Cat#00311; lot# 001972-120331; MW= 622.1
Weigh 311 mg UTP in approximately 4.5 mL of sterile filtered water
pH adjust to 7.0 with 6M NaOH (70+ µL)
Finally volume to 5.0 mL
Filter through 0.22 µm and aliquot about 200µL into Eppendorf tubes

Appendix B
Steps in data processing in Jupyter notebook to get the Guinier plots
Raw UV and X-ray SEC-SAXS data of SHARP2 protein

Single Value Decomposition to find components within the background

SHARP2 UV/X-ray chromatogram after buffer subtraction

Raw UV/X-ray SEC-SAXS data of “treated” STR7 RNA

Single Value Decomposition of “treated” STR7 RNA to find components within the
background

Chromatogram of “treated” STR7 RNA after background subtraction

Raw UV/X-ray SEC-SAXS data of “untreated” STR7 RNA

Single Value Decomposition of “untreated” STR7 RNA to find components within the
background

Chromatogram of “untreated” STR7 RNA after buffer subtraction

Raw UV/X-ray SEC-SAXS data of “treated” STR7 RNA-SHARP2 complex

Single Value Decomposition of “treated” STR7 RNA-SHARP2 complex to find components
within the background

Chromatogram of “treated” STR7 RNA-SHARP2 after buffer
subtraction

I*s^2

Appendix C

(Å)
Å) p(r) of SHARP2
Particle distance distribution,

s (Å-1)
Kratky plot of SHARP2

Top strand STR7 DNA template:
5’ TAA TAC GAC TCA CTA TAG 3’

IDT Company: Bottom strand, STR7 DNA Template:
5’GAC AGG TAT TGA CAA CTT TCC TCC AGC CCA CTG TTC CTG CAG CAG TGC CAG
GCG TCG GCT GAT GTC ATC ACA TAC CTG CCT ATA GTG AGT CGT ATT A 3’

STR 7 domain from SRA1 secondary structures:
5’GGC AGG UAU GUG AUG ACA UCA GCC GAC GCC UGG CAC UGC UGC AGG AAC
AGU GGG CUG GAG GAA AGU UGU CAA UAC CUG UC 3’

Output of STR7 from OligoCalc

RNA fold obtained from entering STR7 sequence in mfold RNA website

HSQC of SHARP RRM 2 (Before desalting)

SEC chromatogram of “treated” STR7 RNA

